Evidence map›Paper›PMID 34055227›Full record

ArticleACS medicinal chemistry letters2021

Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor.

Malcolm P Huestis, Matthew R Durk, Charles Eigenbrot, Paul Gibbons, Thomas L Hunsaker, Hank La, Dennis H Leung, Wendy Liu, Shiva Malek, Mark Merchant and 11 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Hidden Interactions: Quantum Perspectives in Drug Design.Methods in molecular biology (Clifton, N.J.) · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Malcolm P HuestisDiscovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.ORCID 0000-0002-6038-3838
Matthew R DurkDrug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Charles EigenbrotStructural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Paul GibbonsDiscovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Thomas L HunsakerTranslational Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Hank LaDrug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Dennis H LeungSmall Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Wendy LiuDiscovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Shiva MalekMolecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Mark MerchantTranslational Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
John G MoffatBiochemical and Cellular Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Christine S MuliSmall Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Christine J OrrTranslational Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Brendan T ParrDiscovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Frances ShanahanMolecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Christopher J SneeringerBiochemical and Cellular Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Weiru WangStructural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Ivana YenMolecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Jianping YinStructural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Joachim RudolphDiscovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Michael SiuDiscovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.ORCID 0000-0002-2822-6584
Molecular Oncology (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Structure-based optimization of a set of aryl urea RAF inhibitors has led to the identification of Type II pan-RAF inhibitor GNE-9815 (

Identifiers

PMID34055227
PMCPMC8155235
OpenAlexW3155058013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.